Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 3/20 | 0.40 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 3/20 | 0.38 |
| ▸ | MMP8 | P22894 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8477114 | 1.00 | CYP4F2 (0.40) | CYP4F2CYP4A11ALDH1A1PKMMMP8 | |
| SCHEMBL7643873 | 0.83 | CYP4F2 (0.40) | CYP4F2CYP4A11ALDH1A1PKMMMP8 | |
| SCHEMBL1620933 | 0.80 | CYP4F2 (0.41) | CYP4F2CYP4A11ALDH1A1PKMMMP8 | |
| SCHEMBL28072693 | 0.77 | CYP4F2 (0.39) | CYP4F2CYP4A11ALDH1A1PKMMMP8 | |
| SCHEMBL2036323 | 0.76 | ALDH1A1 (0.50) | CYP4F2CYP4A11ALDH1A1PKMMMP8 | |
| SCHEMBL10601256 | 0.75 | CYP4F2 (0.38) | CYP4F2CYP4A11ALDH1A1PKMMMP8 | |
| SCHEMBL8360055 | 0.74 | — | — | |
| SCHEMBL122175 | 0.74 | — | — | |
| SCHEMBL8945034 | 0.74 | ALDH1A1 (0.48) | CYP4F2CYP4A11ALDH1A1PKMMMP8 | |
| SCHEMBL31346451 | 0.74 | CYP4F2 (0.37) | CYP4F2CYP4A11ALDH1A1PKMMMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102036943-A | Preparation of a catalyst containing CF3Method for preparing compounds of O group | MERCK PATENT GMBH | 2011-04-27 | — | — | CN | disclosed |
| US-20110082312-A1 | PRODUCTION OF COMPOUNDS COMPRISING CF30 GROUPS | MERCK PATENT GESELLSCHAFT MIT DESCHRANKTER HAFTUNG (DE) | 2011-04-07 | — | — | US | disclosed |
| US-5973150-A | PHARMACOLOGICAL PROFILE SIMILAR TO THAT OF TRAZODONE BUT ALSO HAVE SOME ADVANTAGES SUCH AS, FOR EXAMPLE, A REDUCED AFFINITY FOR ADRENERGIC RECEPTORS. | ANGELINI RICERCHE S.P.A. SOCIETA' CONSORTILE (IT) | 1999-10-26 | — | — | US | disclosed |
| US-5817815-A | 2-(3-(4-(3-CHLOROPHENYL)-1-(2-METHYL)-PIPERAZINYL)PROPYL)-1,2, 4-TRIAZOLO(4.3-A)PYRIDINE-3(2H)-ONE, ANALGESICS | ANGELINI RICERCHE S.P.A. SOCIETA CONSORTILE (IT) | 1998-10-06 | — | — | US | disclosed |
| US-5741907-A | CYCLIZATION; SALT FORMATION; SEPARATION | ANGELINI RICERCHE S.P.A. SOCIETA' CONSORTILE (IT) | 1998-04-21 | — | — | US | disclosed |
| EP-0707587-B1 | PHARMACOLOGICALLY ACTIVE ENANTIOMERS | ANGELINI RICERCHE SPA (IT) | 1997-10-01 | — | — | EP | disclosed |
| EP-0707587-A1 | PHARMACOLOGICALLY ACTIVE ENANTIOMERS | ANGELINI RICERCHE SPA (IT) | 1996-04-24 | — | — | EP | disclosed |
| WO-1995001354-A1 | PHARMACOLOGICALLY ACTIVE ENANTIOMERS | ANGELINI RICERCHE S.P.A. SOCIETA' CONSORTILE (IT) | 1995-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082312-A1 | PRODUCTION OF COMPOUNDS COMPRISING CF30 GROUPS | ZRANB2, ORC3, IKZF2 | CYP4F2 128/4885CYP4A11 2134/4885ALDH1A1 3861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.